MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$3,377,179
EPS
-$1.29
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Research and development expenses
1,809,209 1,432,138.25* 1,661,646 2,447,286
General and administrative expenses
1,522,005 1,182,127* 1,827,197 1,503,497
Operating loss
-3,331,214 -2,614,265.25* -3,488,843 -3,950,783
Other income
-5,000* --
Unrealized gain on digital assets at fair value
-73,795* --
Unrealized loss on digital assets at fair value
59,824 ---
Interest and dividend income, net
13,859 27,372.75* --
Other income, net
--52,270 16,865
Net operating loss before income tax benefit
-3,377,179 -2,508,097.5 --
Net loss
-3,377,179 -2,508,097.5 -3,436,573 -3,933,918
Basic EPS
-1.29 -1.916 -0.07 -0.25
Diluted EPS
-1.29 -1.916 -0.07 -0.25
Basic Average Shares
2,623,143 1,309,271* 47,525,522 15,569,312
Diluted Average Shares
2,623,143 1,309,271* 47,525,522 15,569,312
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$3,377,179 Net operating lossbefore income tax...-$3,377,179 Interest and dividendincome, net$13,859 Operating loss-$3,331,214 Unrealized loss on digitalassets at fair value$59,824 Research and developmentexpenses$1,809,209 General andadministrative expenses$1,522,005

Processa Pharmaceuticals, Inc. (PCSA)

Processa Pharmaceuticals, Inc. (PCSA)